Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MERRILL K SHUM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1982819702
CMS profile
90154
Location
WHITTIER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,632.06

231 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,141.33 225
Consulting Fee $4,268.00 3
Education $222.73 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $2,482.13 4
Janssen Biotech, Inc. $1,486.23 6
Daiichi Sankyo Inc. $801.44 5
Exelixis Inc. $505.46 9
PFIZER INC. $398.71 25
Celgene Corporation $377.25 13
Merck Sharp & Dohme LLC $339.14 15
Novartis Pharmaceuticals Corporation $247.49 13
Incyte Corporation $222.91 10
Gilead Sciences, Inc. $219.85 12
Pharmacyclics LLC, An AbbVie Company $161.18 9
Takeda Pharmaceuticals U.S.A., Inc. $155.57 5
Eisai Inc. $146.76 7
GlaxoSmithKline, LLC. $145.75 10
Sumitomo Pharma America, Inc. $140.67 6
E.R. Squibb & Sons, L.L.C. $139.58 8
Bayer Healthcare Pharmaceuticals Inc. $137.85 11
Cardinal Health 110 LLC $113.00 2
AstraZeneca Pharmaceuticals LP $101.59 4
Astellas Pharma US Inc $100.49 5
Regeneron Healthcare Solutions, Inc. $96.62 3
Puma Biotechnology, Inc. $80.38 3
BeiGene USA, Inc. $77.69 3
PharmaEssentia USA Corporation $66.58 3
SOBI, INC $63.82 3
MorphoSys, US Inc. $59.57 3
ImmunoGen, Inc. $52.28 2
Seagen Inc. $51.95 2
ARRAY BIOPHARMA INC $49.87 4
EMD Serono, Inc. $49.51 1
Kite Pharma, Inc. $48.57 2
Pharmacosmos Therapeutics Inc. $46.57 2
TAIHO ONCOLOGY, INC. $45.90 2
Ipsen Biopharmaceuticals, Inc $42.63 2
Mirati Therapeutics, Inc. $40.50 2
Deciphera Pharmaceuticals Inc. $33.31 1
Blueprint Medicines Corporation $30.50 1
Karyopharm Therapeutics Inc. $29.84 1
Rigel Pharmaceuticals, Inc. $28.07 2
Genmab U.S., Inc. $27.80 1
Adaptive Biotechnologies Corporation $26.78 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.59 1
Sun Pharmaceutical Industries Inc. $23.21 1
ADC Therapeutics America, Inc. $22.99 1
Agios Pharmaceuticals, Inc. $22.77 1
Verity Pharmaceuticals Inc. $21.12 1
Amgen Inc. $18.30 1
Shield Therapeutics Inc $13.60 1
Lilly USA, LLC $12.69 1

Page 5 of 5; records 201–231 of 231 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MERRILL K SHUM

NPI 1982819702 · CMS profile ID 90154

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WHITTIER, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–231 of 231 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982819702?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–231 of 231 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982819702?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–231 of 231 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982819702?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MERRILL K SHUM, NPI 1982819702, CMS profile ID 90154, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–231 of 231 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1982819702?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

231 matching records · $9,632.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 231 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–231 of 231.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $26.1002/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048663333 CMS
Celgene Corporation $34.1502/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015413409 CMS
GlaxoSmithKline, LLC. $3.0802/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001871965 CMS
Novartis Pharmaceuticals Corporation $25.0202/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993360123 CMS
Verity Pharmaceuticals Inc. $21.1202/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019431291 CMS
E.R. Squibb & Sons, L.L.C. $24.7102/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015413393 CMS
Kite Pharma, Inc. $18.1502/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025273777 CMS
Lilly USA, LLC $12.6902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031842587 CMS
Bayer Healthcare Pharmaceuticals Inc. $0.9802/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000498379 CMS
PFIZER INC. $21.6902/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050547609 CMS
Celgene Corporation $24.5702/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015413417 CMS
Gilead Sciences, Inc. $30.8502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025559413 CMS
Regeneron Healthcare Solutions, Inc. $27.9402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999441725 CMS
TAIHO ONCOLOGY, INC. $19.1902/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055226541 CMS
PFIZER INC. $9.2202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049478761 CMS
E.R. Squibb & Sons, L.L.C. $18.9402/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015413400 CMS
PFIZER INC. $11.3102/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050535645 CMS
Exelixis Inc. $34.4101/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044516091 CMS
Exelixis Inc. $99.9501/30/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044516379 CMS
AstraZeneca Pharmaceuticals LP $24.5101/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015908347 CMS
PFIZER INC. $22.3401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049395587 CMS
AstraZeneca Pharmaceuticals LP $23.0201/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014819567 CMS
Takeda Pharmaceuticals U.S.A., Inc. $47.3601/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055604495 CMS
Novartis Pharmaceuticals Corporation $34.2501/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993360121 CMS
Celgene Corporation $17.9801/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015413361 CMS
PharmaEssentia USA Corporation $23.9501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059316367 CMS
ADC Therapeutics America, Inc. $22.9901/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053786877 CMS
SOBI, INC $18.1601/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038082069 CMS
Janssen Biotech, Inc. $29.9101/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988325309 CMS
Janssen Biotech, Inc. $4.0301/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988325319 CMS
Pharmacyclics LLC, An AbbVie Company $29.2801/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998295623 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,302.02 154
PY2020 $13,851.53 162
PY2021 $6,705.73 184
PY2022 $9,354.03 231
PY2023 $9,632.06 231
PY2024 $16,544.77 283
PY2025 $6,659.04 258

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,326.60 12
PY2024 Principal investigator $183,196.82 12
PY2023 Principal investigator $105,385.99 35
PY2022 Principal investigator $72,151.47 11
PY2021 Principal investigator $254,040.30 58
PY2020 Principal investigator $366,072.31 61
PY2019 Recipient $108.40 1
PY2019 Principal investigator $536,478.32 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $330.75 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.50 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87.75 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.25 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.25 11/21/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/20/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184263067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/30/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184255789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/29/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184254345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 10/09/2025 Non-covered Recipient Entity
HELIOS CR INC
A RANDOMIZED, OPEN-LABEL, C5 INHIBITOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO ARE COMPLEMENT INHIBITOR TREATMENT-NAIVE OR HAVE NOT RECENTLY RECEIVED COMPLEMENT INHIBITOR THERAPY No dispute reported 06/30/2026 1184249322
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10.60 01/09/2025 Non-covered Recipient Entity
THE ONCOLOGY INSTITUTE OF HOPE AND INNOVATION
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab with or without Carboplatinin Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04) No dispute reported 06/30/2026 1185550604